Achilles Therapeutics appoints Carsten Boess to the Board of Directors
07. April 2020 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics appoints Carsten Boess to the Board of Directors Stevenage, UK 7 April, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell...
Achilles Therapeutics appoints Carsten Boess to the Board of Directors
07. April 2020 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics appoints Carsten Boess to the Board of Directors Stevenage, UK 7 April, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell...
Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officer
17. März 2020 08:00 ET
|
Achilles Therapeutics
Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officer - Professor Quezada is an internationally recognized leader in the field of cancer immunology and a founder of the...
Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officer
17. März 2020 03:00 ET
|
Achilles Therapeutics
Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officer - Professor Quezada is an internationally recognized leader in the field of cancer immunology and a founder of the...
Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer
21. Oktober 2019 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Appoints Beverley Carr as Chief Business OfficerBrings 20+ years of business development experience Formerly VP, Business Development for the Immuno-inflammation Therapy Area at...
Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer
21. Oktober 2019 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Appoints Beverley Carr as Chief Business OfficerBrings 20+ years of business development experience Formerly VP, Business Development for the Immuno-inflammation Therapy Area at...
Achilles Therapeutics raises £100 million in oversubscribed Series B financing
03. September 2019 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics raises £100 million in oversubscribed Series B financing - Leading international syndicate led by RA Capital and cornerstoned by founding investor Syncona- Confirms depth of...
Achilles Therapeutics raises £100 million in oversubscribed Series B financing
03. September 2019 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics raises £100 million in oversubscribed Series B financing - Leading international syndicate led by RA Capital and cornerstoned by founding investor Syncona- Confirms depth of...
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma
13. Februar 2019 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma Second CTA approval in 2019 – the first was for a NSCLC study Stevenage, UK 13 February...
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma
13. Februar 2019 03:00 ET
|
Achilles Therapeutics
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma Second CTA approval in 2019 – the first was for a NSCLC study Stevenage, UK 13 February...